Apyx Medical (NASDAQ:APYX) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Apyx Medical (NASDAQ:APYX) announced its quarterly earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05, FiscalAI reports. The company had revenue of $14.03 million for the quarter, compared to analysts’ expectations of $13.29 million. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%.

Here are the key takeaways from Apyx Medical’s conference call:

• Apyx reported third-quarter revenue of $14 million, up 9% year over year, led by 17% growth in Surgical Aesthetics. OEM revenue fell 41.5%, partially offsetting that growth.
• The company said AYON’s power-liposuction rollout is underway and surgeon feedback has been positive; management sees additional growth potential as it pursues regulatory approvals in international markets, though it gave no approval timelines.
• Apyx reported positive EBITDA on a trailing 12-month basis and $0.4 million in adjusted EBITDA for the quarter, versus a loss a year earlier. Operating cash use also declined year over year, and cash stood at $25.8 million at quarter-end.
• Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million and lowered its operating-expense target to $41 million–$42.5 million from less than $45 million. It now expects full-year gross margins of 63%–64%.

Apyx Medical Stock Performance

Shares of Apyx Medical stock opened at $2.93 on Friday. Apyx Medical has a 52 week low of $2.25 and a 52 week high of $5.08. The business has a 50 day moving average price of $2.74 and a 200-day moving average price of $3.58. The company has a market cap of $123.41 million, a PE ratio of -15.42 and a beta of 1.47. The company has a quick ratio of 4.53, a current ratio of 5.68 and a debt-to-equity ratio of 3.19.

Key Headlines Impacting Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q3 revenue was $14.0 million, above analysts’ $13.29 million estimate, while the per-share loss of $0.04 was narrower than expected. Surgical Aesthetics revenue grew 17%, and Apyx said it successfully launched its power liposuction handpiece for the AYON system. Apyx Medical third-quarter 2026 results
• Positive Sentiment: Management reaffirmed 2026 revenue guidance of $59 million to $60 million and lowered its operating expense target to $41 million–$42.5 million, a cost-control signal. The revenue range brackets the $59.4 million consensus estimate. Apyx reaffirms guidance and tightens expense target
• Negative Sentiment: Apyx remains unprofitable: it posted a quarterly loss, and its reported net margin and return on equity were negative. Continued losses may temper the market’s response to the revenue beat and new product launch. Apyx reports Q3 loss and tops revenue estimates

Wall Street Analyst Weigh In

APYX has been the subject of a number of research reports. Maxim Group initiated coverage on shares of Apyx Medical in a report on Tuesday, September 29th. They issued a “buy” rating and a $6.00 price objective for the company. HC Wainwright assumed coverage on shares of Apyx Medical in a research note on Monday, July 13th. They set a “buy” rating and a $7.00 price objective for the company. Zacks Research upgraded Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research note on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Apyx Medical presently has an average rating of “Moderate Buy” and an average price target of $6.50.

Apyx Medical Company Profile

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.